{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:56:20Z","timestamp":1781272580540,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Meda, a Mylan Company"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Imiquimod 3.75% is a field\u2010directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun\u2010exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (<jats:italic>L<\/jats:italic><jats:sub>max<\/jats:sub>). We report clinical outcomes for the first 15 patients treated with imiquimod 3.75% in daily clinical practice in Greece.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifteen patients with actinic keratosis lesions were treated with imiquimod 3.75% in an outpatient setting in two 2\u2010week treatment cycles separated by a 2\u2010week treatment\u2010free interval. Actinic keratosis lesions were counted before treatment, at the end of the first treatment cycle (Week 2; <jats:italic>L<\/jats:italic><jats:sub>max<\/jats:sub>), and 2\u00a0weeks after the second treatment cycle (Week 8). Local skin reactions (LSR) were also evaluated at Weeks 2 and 8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median baseline actinic keratosis lesion count was 25, which increased to a median <jats:italic>L<\/jats:italic><jats:sub>max<\/jats:sub> of 29 at Week 2 and decreased to a median of 5 at Week 8. The median percentage and absolute reduction in actinic keratosis lesions from <jats:italic>L<\/jats:italic><jats:sub>max<\/jats:sub> to Week 8 were 87% and 23%, respectively. Most of the LSR were mild\u2010to\u2010moderate in intensity at Week 2 and had resolved by Week 8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Imiquimod 3.75% effectively detected and cleared both the clinical and subclinical actinic keratosis lesions across the entire sun\u2010exposed field in this cohort of Greek patients. Treatment was well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.14397","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T12:14:54Z","timestamp":1550578494000},"page":"1040-1044","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Imiquimod 3.75% for field\u2010directed therapy of actinic keratosis: results of a prospective case\u2010series study in Greece"],"prefix":"10.1111","volume":"58","author":[{"given":"Angeliki","family":"Befon","sequence":"first","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Tzanetakou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Panagiotopoulos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Chasapi","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Antoniou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-5694","authenticated-orcid":false,"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology\u2010Venereology National and Kapodistrian University of Athens and State Department of Dermatology\u2010Venereology Andreas Sygros Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"issue":"1","key":"e_1_2_5_2_1","first-page":"3","article-title":"Actinic keratosis and field cancerisation","volume":"21","author":"Stockfleth E","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13180"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366525"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14092"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12848"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12824"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13235"},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: a new concept for assessing efficacy of field\u2010directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockfleth E","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12782"},{"key":"e_1_2_5_11_1","first-page":"285","article-title":"Efficacy and safety of imiquimod 3.75% from Lmax in actinic keratosis according to Fitzpatrick skin type","volume":"15","author":"Alomar A","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12697"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13260"},{"key":"e_1_2_5_14_1","unstructured":"Highlights of prescribing information: Zyclara (imiquimod) cream 3.7%. For topical use only. NDA022483. Revised March2010. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/090075lbl.pdfLast accessed 17 May 2018."},{"key":"e_1_2_5_15_1","first-page":"7","article-title":"A study of demographic characteristics and exposure to known risk factors of Greek patients with actinic keratoses","volume":"26","author":"Chatzinasiou F","year":"2015","journal-title":"Hellenic Dermato\u2010Veneological Review"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12829"},{"key":"e_1_2_5_18_1","first-page":"333","article-title":"Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series","volume":"153","author":"Tambone S","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_5_19_1","first-page":"5","article-title":"Current management of actinic keratoses","volume":"15","author":"Shoimer I","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.549128"},{"key":"e_1_2_5_21_1","first-page":"165","article-title":"Complete clearance is sustained for at least 12\u00a0months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke CW","year":"2011","journal-title":"J Drugs Dermatol"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.14397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.14397","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T23:37:02Z","timestamp":1694302622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.14397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/ijd.14397"],"URL":"https:\/\/doi.org\/10.1111\/ijd.14397","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"2018-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}